The SCOPE Scientific Symposium (SSS)
Tuesday: February 18, 2020 from 3:00 to 5:00 pm at CHI’s SCOPE Summit in Orlando
The new SSS provides a forum where academics, sponsors, CROs, and other parties who share a common interest in the conduct of clinical trials can discuss the latest and most promising research that advances how we run clinical trials. We are focusing on research to improve a process that in many ways is outdated and in dire need for efficiencies. The panelists will discuss promising research and technologies that can bring data-driven, scientific practices to clinical research design and execution. These improvements should result in better decisions in new drug evaluations; providing patients with broader and more rapid access to novel medications. The panel discussion will feature the committee members below, all thought leaders, sharing ideas in a collegial atmosphere.
- Attending: There is no added cost to attend this event at SCOPE, but Attendees and Speakers must be registered as a “Best Value” SCOPE conference participant (using discount code SSS). If you would like to attend, please contact us.
Program Committee and Panelists
Kyle Holen, MD, Head, Development Design Center, Research & Development, AbbVie
Michelle Crouthamel, PhD, Director, Digital Health & Innovation, AbbVie
Mary Jo Lamberti, PhD, Associate Director and Research Assistant Professor, Tufts Center for the Study of Drug Development (CSDD)
Craig Lipset, MBA, Former Head, Clinical Innovation, Pfizer; Venture Partner, Boston Millennia Partners (BMP) & FundRx; Advisor, People-Centered Research Foundation (PCRF)
Gabriela Feldberg, Leader, Advanced Analytics Center of Excellence, AstraZeneca Pharmaceuticals Inc
Antonieta Sosa, Director Clinical Innovation, Clinical Innovation, Janssen R&D LLC
Oriol Serra Ortiz, MBA, Senior Director & Head, Global Site Intelligence & Selection, Pfizer Inc
Angelique Hopkins, Director, Clinical Trial Analytics, Business Insights and Analytics, Bristol-Myers Squibb Co
Adama Ibrahim, EMBA, Associate Director Performace Operational Capabilities, Global Clinical Operations, Biogen Ltd
Balazs Flink, MD, Head, Clinical Trial Analytics R&D Business Insights, Bristol Myers Squibb Co
Carrie Melvin, Vice President & Head, Global Clinical Operations, TESARO
Micah Lieberman, Executive Director, Conferences, Cambridge Healthtech Institute (CHI)
Marina Filshtinsky, MD, Executive Director, Conferences, Cambridge Healthtech Institute (CHI)
ABOUT THE EVENT
Celebrating its 11th successful year, SCOPE Summit 2020 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 20 different conferences, 3 plenary keynote sessions, the annual Participant Engagement Awards, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including: Site Selection and Management, Patient Engagement, Recruitment and Retention, Protocol Optimization, Feasibility, Data Strategy and Analytics, Sensors and Wearables, Project Management, Outsourcing, Forecasting, Budgeting and Contracting, Resource Management, Quality (QbD) in Trial Conduct, Risk-Based Monitoring, Artificial Intelligence, Post-Marketing Studies, Observational Research, Accessing and Generating RWD, Clinical Biomarker Strategy, Clinical Supply Chain, Precision Medicine, Clinical Biomarkers and Biospecimens, and Central Lab Solutions, and an all new track on Medical Device Clinical Trial Operations and Regulations.
SCOPE 2019 attracted record attendance with more than 2,000 participants
A Leader in the Clinical Trial Industry: SCOPE Grows by 20% for the fourth consecutive year
2019 Event Featured
- 2,000+ participants
- 19 conferences
- Participant Engagement Awards
- Dedicated Exhibit Hall Hours & Networking Functions
- Interactive Breakout Discussions
- Greater Gift Vaccine Dontations
The impressive executive audience at SCOPE came together for invaluable networking opportunities with more than 52% of the attendees titled as a decision maker from leading Pharma (20%), CRO (35%), and Biotech companies (20%). Industry leaders and key decision makers representing 28 different countries and more than 700 unique organizations shared case studies, collaborated on best practices and provided unique perspectives on poignant issues that the field currently faces.
2019 Attendee Demographics
* The program is subject to change without notice, due to unforeseen reason.